TrialPath
Rheumatoid arthritis · Denver

Rheumatoid arthritis clinical trials in Denver

9 recruiting rheumatoid arthritis studies within range of Denver. Click any trial for full eligibility criteria and contact info.

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

NCT07403188 · Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome
Recruiting

The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).

Phase
TypeObservational
Age18 Years
WhereDenver, Colorado, United States
SponsorKyverna Therapeutics
Tap for details
Apply

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis
Recruiting

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.

PhasePhase 2
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 151 more
SponsorAvalyn Pharma Inc.
Tap for details
Apply

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Recruiting

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).

PhasePhase 1
TypeInterventional
Age18 Years
WhereAurora, Colorado, United States + 53 more
SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
Tap for details
Apply

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

NCT07404865 · Primary Sjogren's Disease
Recruiting

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)

PhasePhase 3
TypeInterventional
Age18 Years – 75 Years
WhereChandler, Arizona, United States + 25 more
SponsorVor Biopharma
Tap for details
Apply

Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)

NCT05787821 · Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis
Recruiting

The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty

Phase
TypeObservational
Age18 Years
WhereParker, Colorado, United States + 15 more
SponsorZimmer Biomet
Tap for details
Apply

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

NCT06397677 · Rheumatoid Arthritis, Interstitial Lung Disease
Recruiting

A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.

Phase
TypeObservational
Age18 Years – 90 Years
WhereSan Francisco, California, United States + 3 more
SponsorUniversity of Colorado, Denver
Tap for details
Apply

G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study

NCT04754087 · Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip
Recruiting

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.

PhaseNA
TypeInterventional
Age18 Years
WhereDenver, Colorado, United States + 10 more
SponsorZimmer Biomet
Tap for details
Apply

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Recruiting

This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled. The number of participants can be extended to maximally 220 to account for dropouts during the study.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereGilbert, Arizona, United States + 28 more
SponsorElevara Medicines Limited
Tap for details

Exactech Shoulder Post Market Clinical Follow-up Study

NCT05603728 · Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears
Recruiting

The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.

Phase
TypeObservational
Age21 Years
WhereLaguna Woods, California, United States + 37 more
SponsorExactech
Tap for details
Apply